Role of the adenosine system and glucose restriction in the acute anticonvulsant effect of caprylic acid in the 6Hz psychomotor seizure test in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 57, Issue , 2015, Pages 44-51

  Socała, Katarzyna ^a   Nieoczym, Dorota ^a   Pieróg, Mateusz ^a   Wlaź, Piotr ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

6Hz seizure test; Adenosine; Caprylic acid; Mice1

Indexed keywords

3 HYDROXYBUTYRIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; DIPYRIDAMOLE; GLIBENCLAMIDE; GLUCOSE; ISTRADEFYLLINE; OCTANOIC ACID; POTASSIUM CHANNEL BLOCKING AGENT; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; OCTANOIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PURINE DERIVATIVE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD PH; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GRIP STRENGTH; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; SEIZURE; SEIZURE THRESHOLD; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DEFICIENCY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; PH; SEIZURES;

3-HYDROXYBUTYRIC ACID; ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTICONVULSANTS; BLOOD GLUCOSE; CAPRYLATES; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FASTING; GLUCOSE; GLYBURIDE; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; MALE; MICE; MOTOR SKILLS; MUSCLE STRENGTH; PHOSPHODIESTERASE INHIBITORS; PURINES; SEIZURES; XANTHINES;

EID: 84910023495     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.10.006     Document Type: Article

References (42)

1. Akula K.K., Dhir A., Kulkarni S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res 2008, 78:60-70.
2. Bach A.C., Babayan V.K. Medium-chain triglycerides: an update. Am J Clin Nutr 1982, 36:950-962.
3. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47:217-227.
4. Boison D. Adenosine dysfunction in epilepsy. Glia 2012, 60:1234-1243.
5. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle methode simple pour explorer l'action 'tranquilistante': le test de la cheminee. Med Exp (Basel) 1960, 3:81-84.
6. Budni J., Freitas A.E., Binfare R.W., Rodrigues A.L. Role of potassium channels in the antidepressant-like effect of folic acid in the forced swimming test in mice. Pharmacol Biochem Behav 2012, 101:148-154.
7. Clark R.H., McTaggart J.S., Webster R., Mannikko R., Iberl M., Sim X.L., et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science 2010, 329:458-461.
8. Danial N.N., Hartman A.L., Stafstrom C.E., Thio L.L. How does the ketogenic diet work? Four potential mechanisms. J Child Neurol 2013, 28:1027-1033.
9. Freeman J.M., Kossoff E.H., Hartman A.L. The ketogenic diet: one decade later. Pediatrics 2007, 119:535-543.
10. Hartman A.L., Gasior M., Vining E.P., Rogawski M.A. The neuropharmacology of the ketogenic diet. Pediatr Neurol 2007, 36:281-292.
11. Hartman A.L., Zheng X., Bergbower E., Kennedy M., Hardwick J.M. Seizure tests distinguish intermittent fasting from the ketogenic diet. Epilepsia 2010, 51:1395-1402.
12. Huttenlocher P.R., Wilbourn A.J., Signore J.M. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971, 21:1097-1103.
13. Kawamura M., Ruskin D.N., Masino S.A. Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors, and KATP channels. J Neurosci 2010, 30:3886-3895.
14. Kimball A.W., Burnett W.T., Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat Res 1957, 7:1-12.
15. Kochanek P.M., Vagni V.A., Janesko K.L., Washington C.B., Crumrine P.K., Garman R.H., et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 2006, 26:565-575.
16. Kossoff E.H., Rho J.M. Ketogenic diets: evidence for short- and long-term efficacy. Neurotherapeutics 2009, 6:406-414.
17. Li D.P., Chen S.R., Pan H.L. Adenosine inhibits paraventricular pre-sympathetic neurons through ATP-dependent potassium channels. J Neurochem 2010, 113:530-542.
18. Li X., Kang H., Liu X., Liu Z., Shu K., Chen X., et al. Effect of adenosine A2A receptor antagonist ZM241385 on amygdala-kindled seizures and progression of amygdala kindling. J Huazhong Univ Sci Technolog Med Sci 2012, 32:257-264.
19. Li M., Kang R., Shi J., Liu G., Zhang J. Anticonvulsant activity of B2, an adenosine analog, on chemical convulsant-induced seizures. PLoS One 2013, 8:e67060.
20. Lipman J.J., Spencer P.S. Rapid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods 1980, 4:327-333.
21. Liu M.J., Pollack G.M. Pharmacokinetics and pharmacodynamics of valproate analogues in rats. IV. Anticonvulsant action and neurotoxicity of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Epilepsia 1994, 35:234-243.
22. Liu Y.M., Wang H.S. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J 2013, 36:9-15.
23. Löscher W., Klotz U., Zimprich F., Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009, 50:1-23.
24. Lutas A., Yellen G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci 2013, 36:32-40.
25. Ma W., Berg J., Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels. J Neurosci 2007, 27:3618-3625.
26. Masino S.A., Rho J.M. Mechanisms of ketogenic diet action. Jasper's basic mechanisms of the epilepsies 2012, National Center for Biotechnology Information (US), Bethesda (MD). J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
27. Masino S.A., Kawamura M., Wasser C.D., Pomeroy L.T., Ruskin D.N. Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity. Curr Neuropharmacol 2009, 7:257-268.
28. Masino S.A., Li T., Theofilas P., Sandau U.S., Ruskin D.N., Fredholm B.B., et al. A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors. J Clin Invest 2011, 121:2679-2683.
29. Masino S.A., Kawamura M., Ruskin D.N., Geiger J.D., Boison D. Purines and neuronal excitability: links to the ketogenic diet. Epilepsy Res 2012, 100:229-238.
30. Maurissen J.P., Marable B.R., Andrus A.K., Stebbins K.E. Factors affecting grip strength testing. Neurotoxicol Teratol 2003, 25:543-553.
31. McDonald T.S., Tan K.N., Hodson M.P., Borges K. Alterations of hippocampal glucose metabolism by even versus uneven medium chain triglycerides. J Cereb Blood Flow Metab 2014, 34:153-160.
32. Nandhakumar J., Tyagi M. Evaluation of seizure activity after phospho-diesterase and adenylate cyclase inhibition (SQ22536) in animal models of epilepsy. Indian J Sci Technol 2010, 3:710-717.
33. Neal E.G., Chaffe H., Schwartz R.H., Lawson M.S., Edwards N., Fitzsimmons G., et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 2009, 50:1109-1117.
34. Payne N.E., Cross J.H., Sander J.W., Sisodiya S.M. The ketogenic and related diets in adolescents and adults-a review. Epilepsia 2011, 52:1941-1948.
35. Perlman B.J., Goldstein D.B. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol Pharmacol 1984, 26:83-89.
36. Pfeifer H.H., Thiele E.A. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology 2005, 65:1810-1812.
37. Spector R. Fatty acid transport through the blood-brain barrier. J Neurochem 1988, 50:639-643.
38. Traul K.A., Driedger A., Ingle D.L., Nakhasi D. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000, 38:79-98.
39. Wallace T.M., Matthews D.R. Recent advances in the monitoring and management of diabetic ketoacidosis. QJM 2004, 97:773-780.
40. Wang C., Lin W., Playa H., Sun S., Cameron K., Buolamwini J.K. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol 2013, 86:1531-1540.
41. Wlaź P., Socała K., Nieoczym D., Łuszczki J.J., Z˙arnowska I., Z˙arnowski T., et al. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology 2012, 62:1882-1889.
42. Yamada K., Kobayashi M., Mori A., Jenner P., Kanda T. Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav 2013, 114-115:23-30.